Key result
Between 2014 and 2017, the prevalence of non-valvular atrial fibrillation increased from 1.90% to 2.20%, while DOAC prescriptions among these patients increased from 30% to 57%.
Why the study?
DOACs effectively reduce thromboembolism in NVAF, but little is known regarding daily clinical practice trends in NVAF prevalence and DOAC prescriptions.
Cross-Sectional (n=57,452)
Between 2014 and 2017 in a Japanese region, NVAF prevalence and DOAC use increased significantly, though 17% of high-risk patients (CHADS2 ≥2) remained without oral anticoagulation.
BACKGROUND: Direct oral anticoagulants (DOACs) are effective in reducing thromboembolism events in patients with non-valvular atrial fibrillation (NVAF). However, little is known about trends in NVAF prevalence and DOAC prescriptions in daily clinical practice. This study investigated the current status and trends in NVAF prevalence and DOAC prescriptions in a region of Japan. METHODS AND RESULTS: score ≥2 were not prescribed an OAC in 2017. CONCLUSIONS: By using the KDB we found that the prevalence of NVAF has increased gradually from 2014 to 2017. In the Tsugaru region in Japan, DOACs prescriptions increased and warfarin prescriptions decreased over the 4-year period.
No takes yet. Share an insight, caveat, or question.
Narita et al. (2020) conducted a cross-sectional in Non-valvular atrial fibrillation (NVAF) (n=57,452). Time period (2017) vs. Time period (2014) was evaluated on DOAC prescription rate among NVAF patients (p=<0.0001). Between 2014 and 2017, the prevalence of non-valvular atrial fibrillation increased from 1.90% to 2.20%, while DOAC prescriptions among these patients increased from 30% to 57%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: